The sneaky, unregulated dangers of copycat GLP-1 drugs
Federal regulators are turning up the heat on sellers of copycat weight-loss drugs. Earlier this summer, the Food and Drug Administration sent warning letters to dozens of companies marketing compounded GLP-1s over misleading advertising. That action…
